{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:20Z","timestamp":1783075940276,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is little evidence-based guidance on how to optimize methadone dosages among patients with opioid addiction undergoing methadone maintenance treatment (MMT). This study aims to investigate whether self-perceived opioid withdrawal symptoms, adverse effects, and self-reported substance use in patients on MMT are related to serum methadone concentrations and the role that these variables could play in clinical decisions on dose adjustments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This naturalistic prospective cohort study included clinical and laboratory measurements from 83 patients undergoing MMT in outpatient clinics in Bergen, Norway, from May 2017 to January 2020. Information on age, gender, methadone daily doses and serum concentrations, subjective opioid withdrawal symptoms using 16 items Subjective Opioid Withdrawal Scale (SOWS) questionnaire, self-reported adverse effects, and substance use was obtained. Linear mixed modelling was used for analyzing the data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of the participants was 45\u2009years, and 33% were women. Almost half reported mild to moderate subjective opioid withdrawal symptoms, and all had experienced at least one subjective adverse effect. The use of at least one substance was reported by 88% of the participants. Serum concentration-to-dose ratios were lower among those who had reported subjective opioid withdrawal symptoms (<jats:italic>p)<\/jats:italic>\u2009=\u20090.039). The total SOWS score (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); the specific subjective withdrawal symptoms of anxiety (<jats:italic>p<\/jats:italic>\u2009=\u20090.004), bone and muscle aches (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), restlessness (<jats:italic>p<\/jats:italic>\u2009=\u20090.017), and (slightly) shaking (<jats:italic>p<\/jats:italic>\u2009=\u20090.046), also use of heroin (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) and alcohol (<jats:italic>p<\/jats:italic>\u2009=\u20090.011) were associated with lower methadone concentrations. Cannabis use was slightly related to higher methadone concentrations (<jats:italic>p<\/jats:italic>\u2009=\u20090.049).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings suggest that the patient\u2019s self-perceived symptoms and current clinical condition are related to the serum concentrations of methadone. This interpretation supports dose adjustments based on patient-reported symptoms. In some aberrant cases, measurement of serum concentrations together with other individual assessments may be considered to support the clinical decision.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-021-00367-w","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T10:03:10Z","timestamp":1620036190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1242-1972","authenticated-orcid":false,"given":"Fatemeh","family":"Chalabianloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"H\u00f8iseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ohldieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn Henrik","family":"Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen G.","family":"Bramness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"4","key":"367_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","volume":"28","author":"L Amato","year":"2005","unstructured":"Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321\u20139. Review. https:\/\/doi.org\/10.1016\/j.jsat.2005.02.007.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"367_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2013.05.022","volume":"133","author":"L Gjersing","year":"2013","unstructured":"Gjersing L, Bretteville-Jensen AL. Is opioid substitution treatment beneficial if injecting behaviour continues? Drug Alcohol Depend. 2013;133(1):121\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.05.022.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"367_CR3","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2019","unstructured":"Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868\u201383. https:\/\/doi.org\/10.1038\/s41380-018-0094-5.","journal-title":"Mol Psychiatry"},{"key":"367_CR4","first-page":"357","volume":"6","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;6:357 Review.","journal-title":"BMJ."},{"issue":"1","key":"367_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10550880903436010","volume":"29","author":"A Fareed","year":"2010","unstructured":"Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis. 2010;29(1):1\u201314. https:\/\/doi.org\/10.1080\/10550880903436010.","journal-title":"J Addict Dis"},{"issue":"14","key":"367_CR6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153\u201393. https:\/\/doi.org\/10.2165\/00003088-200241140-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"367_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.clinbiochem.2005.09.009","volume":"38","author":"DC Lehotay","year":"2005","unstructured":"Lehotay DC, George S, Etter ML, Graybiel K, Eichhorst JC, Fern B, et al. Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage? Clin Biochem. 2005;38(12):1088\u201394. https:\/\/doi.org\/10.1016\/j.clinbiochem.2005.09.009.","journal-title":"Clin Biochem"},{"issue":"3","key":"367_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1300\/J069v21n03_01","volume":"21","author":"S Maxwell","year":"2002","unstructured":"Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis. 2002;21(3):1\u201312. https:\/\/doi.org\/10.1300\/J069v21n03_01.","journal-title":"J Addict Dis"},{"issue":"3","key":"367_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart G. Maintenance medication for opiate addiction: the Foundation of Recovery. J Addict Dis. 2012;31(3):207\u201325. https:\/\/doi.org\/10.1080\/10550887.2012.694598.","journal-title":"J Addict Dis"},{"key":"367_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2018.02.018","volume":"187","author":"AE Muller","year":"2018","unstructured":"Muller AE, Bjornestad R, Clausen T. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. Drug Alcohol Depend. 2018;187:22\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.02.018.","journal-title":"Drug Alcohol Depend"},{"issue":"5-6","key":"367_CR11","first-page":"404","volume":"67","author":"SB Leavitt","year":"2000","unstructured":"Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When \u201cenough\u201d is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 2000;67(5-6):404\u201311.","journal-title":"Mt Sinai J Med"},{"issue":"6","key":"367_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/bcp.12576","volume":"79","author":"S Mouly","year":"2015","unstructured":"Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, et al. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015;79(6):967\u201377. https:\/\/doi.org\/10.1111\/bcp.12576.","journal-title":"Br J Clin Pharmacol"},{"issue":"9148","key":"367_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0140-6736(98)05356-2","volume":"353","author":"J Ward","year":"1999","unstructured":"Ward J, Hall W, Mattick RP. Role of methadone treatment in opioid dependence. Lancet. 1999;353(9148):221\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(98)05356-2.","journal-title":"Lancet"},{"issue":"3","key":"367_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/15622975.2011.561872","volume":"12","author":"M Soyka","year":"2011","unstructured":"Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S. The world Federation of Societies of biological psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry. 2011;12(3):160\u201387. https:\/\/doi.org\/10.3109\/15622975.2011.561872.","journal-title":"World J Biol Psychiatry"},{"issue":"11","key":"367_CR15","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s00213-019-05277-1","volume":"236","author":"F Chalabianloo","year":"2019","unstructured":"Chalabianloo F, Westin AA, Skogvoll E, Bramness JG, Spigset O. Methadone serum concentrations and influencing factors: a naturalistic observational study. Psychopharmacology. 2019;236(11):3159\u201367. https:\/\/doi.org\/10.1007\/s00213-019-05277-1.","journal-title":"Psychopharmacology"},{"issue":"5","key":"367_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/FTD.0000000000000437","volume":"39","author":"MK Kringen","year":"2017","unstructured":"Kringen MK, Chalabianloo F, Bernard JP, Bramness JG, Molden E, H\u00f8iseth G. Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment. Ther Drug Monit. 2017;39(5):550\u20135. https:\/\/doi.org\/10.1097\/FTD.0000000000000437.","journal-title":"Ther Drug Monit"},{"key":"367_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1520\/JFS2002424","volume":"48","author":"A Gagajewski","year":"2003","unstructured":"Gagajewski A, Apple FS. Methadone-related deaths in Hennepin County Minnesota: 1992-2002. J Forensic Sci. 2003;48:1\u20134.","journal-title":"J Forensic Sci"},{"issue":"1","key":"367_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000485029","volume":"24","author":"G Mannaioni","year":"2018","unstructured":"Mannaioni G, Lanzi C, Lotti M, Galli V, Totti A, Pacileo I, et al. Methadone dose adjustments, plasma R-methadone levels and therapeutic outcome of heroin users: a randomized clinical trial. Eur Addict Res. 2018;24(1):9\u201318. https:\/\/doi.org\/10.1159\/000485029.","journal-title":"Eur Addict Res"},{"key":"367_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fgene.2018.00450","volume":"9","author":"S Peng","year":"2018","unstructured":"Peng S, Jiang H, Du J, Lin S, Pan S, Yu S, et al. Methadone dosage and plasma levels, SNPs of OPRM1 gene and age of first drug use were associated with outcomes of methadone maintenance treatment. Front Genet. 2018;9:450. https:\/\/doi.org\/10.3389\/fgene.2018.00450.","journal-title":"Front Genet"},{"issue":"6","key":"367_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","volume":"78","author":"S Crettol","year":"2005","unstructured":"Crettol S, D\u00e9glon J-J, Besson J, Croquette-Krokkar M, Gothuey I, H\u00e4mmig R, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78(6):593\u2013604. https:\/\/doi.org\/10.1016\/j.clpt.2005.08.011.","journal-title":"Clin Pharmacol Ther"},{"key":"367_CR21","volume-title":"Principles of addiction medicine","author":"RK Ries","year":"2009","unstructured":"Ries RK, Fiellin DA, Miller SC, Saitz R. Principles of addiction medicine. 4th ed. Philadelphia: Medicine & Health Sciences; 2009.","edition":"4"},{"issue":"20","key":"367_CR22","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1001\/jama.1988.03410200081030","volume":"260","author":"VP Dole","year":"1988","unstructured":"Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260(20):3025\u20139. https:\/\/doi.org\/10.1001\/jama.1988.03410200081030.","journal-title":"JAMA."},{"issue":"1","key":"367_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","volume":"61","author":"CB Eap","year":"2000","unstructured":"Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 2000;61(1):47\u201354. https:\/\/doi.org\/10.1016\/S0376-8716(00)00121-6.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"367_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0009-9236(99)90090-5","volume":"65","author":"KR Dyer","year":"1999","unstructured":"Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther. 1999;65(6):685\u201394. https:\/\/doi.org\/10.1016\/S0009-9236(99)90090-5.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"367_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","volume":"13","author":"L Handelsman","year":"1987","unstructured":"Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293\u2013308. https:\/\/doi.org\/10.3109\/00952998709001515.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"367_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/10550881003684798","volume":"29","author":"MJ Kreek","year":"2010","unstructured":"Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis. 2010;29(2):200\u201316. https:\/\/doi.org\/10.1080\/10550881003684798.","journal-title":"J Addict Dis"},{"issue":"5","key":"367_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5055\/jom.2013.0175","volume":"9","author":"TA Macey","year":"2013","unstructured":"Macey TA, Weimer MB, Grimaldi EM, Dobscha SK, Morasco BJ. Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain. J Opioid Manag. 2013;9(5):325\u201333. https:\/\/doi.org\/10.5055\/jom.2013.0175.","journal-title":"J Opioid Manag"},{"key":"367_CR28","first-page":"Cd012509","volume":"10","author":"C Els","year":"2017","unstructured":"Els C, Jackson TD, Kunyk D, Lappi VG, Sonnenberg B, Hagtvedt R, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of cochrane reviews. Cochrane Database Syst Rev. 2017;10:Cd012509.","journal-title":"Cochrane Database Syst Rev"},{"key":"367_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.forsciint.2012.11.010","volume":"10","author":"J-P Bernard","year":"2013","unstructured":"Bernard J-P, Havnes I, Sl\u00f8rdal L, Waal H, M\u00f8rland J, Khiabani HZ. Methadone-related deaths in Norway. Forensic Sci Int. 2013;10:111\u20136.","journal-title":"Forensic Sci Int"},{"issue":"8","key":"367_CR30","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1360-0443.2004.00764.x","volume":"99","author":"TB Mitchell","year":"2004","unstructured":"Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction. 2004;99(8):940\u20135. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00764.x.","journal-title":"Addiction"},{"issue":"7","key":"367_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2217\/pgs.13.58","volume":"14","author":"O Levran","year":"2013","unstructured":"Levran O, Peles E, Randesi M, Shu X, Ott J, Shen P-H, et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013;14(7):755\u201368. https:\/\/doi.org\/10.2217\/pgs.13.58.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"367_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00213-002-1027-0","volume":"161","author":"EC Donny","year":"2002","unstructured":"Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid dependent humans. Psychopharmacology. 2002;161(2):202\u201312. https:\/\/doi.org\/10.1007\/s00213-002-1027-0.","journal-title":"Psychopharmacology"},{"issue":"10","key":"367_CR33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/j.1360-0443.2005.01232.x","volume":"100","author":"EC Donny","year":"2005","unstructured":"Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005;100(10):1496\u2013509. https:\/\/doi.org\/10.1111\/j.1360-0443.2005.01232.x.","journal-title":"Addiction"},{"key":"367_CR34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archpsyc.57.4.395","volume":"57","author":"KL Preston","year":"2000","unstructured":"Preston KL, Umbrichat A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57:395\u2013404.","journal-title":"Arch Gen Psychiatry"},{"key":"367_CR35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pnpbp.2015.07.011","volume":"65","author":"W Berrettini","year":"2015","unstructured":"Berrettini W. Alcohol addiction and the mu-opioid receptor. Prog Neuropsychopharmacol Biol Psychiatry. 2015;65:228\u201333.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"24","key":"367_CR36","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456\u201373. https:\/\/doi.org\/10.1001\/jama.2015.6358.","journal-title":"JAMA."},{"issue":"3","key":"367_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1360-0443.1998.9333212.x","volume":"93","author":"NM Petry","year":"1998","unstructured":"Petry NM, Bickel WK. Polydrug abuse in heroin addicts: a behavioral economic analysis. Addiction. 1998;93(3):321\u201335. https:\/\/doi.org\/10.1046\/j.1360-0443.1998.9333212.x.","journal-title":"Addiction"},{"issue":"3","key":"367_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1360-0443.2003.00310.x","volume":"98","author":"DH Epstein","year":"2003","unstructured":"Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? A review of past findings, and more evidence against. Addiction. 2003;98(3):269\u201379. https:\/\/doi.org\/10.1046\/j.1360-0443.2003.00310.x.","journal-title":"Addiction"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-021-00367-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T10:27:06Z","timestamp":1620037626000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-021-00367-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1186\/s13011-021-00367-w","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Committee for Medical and Health Research Ethics in Vest Norway (approval No. 2017\/297\/REK vest). All participants had signed a written informed consent on agreement about using of routine and research data for this purpose and for taking part in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants have consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}